within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01F_MacrolidesLincosamidesAndStreptogramins.J01FF01_Clindamycin;

model Clindamycin
  extends Pharmacolibrary.Drugs.ATC.J.J01FF01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01FF01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Clindamycin is a lincosamide antibiotic used for the treatment of a variety of serious bacterial infections, particularly those caused by susceptible anaerobic bacteria, streptococci, staphylococci, and pneumococci. It is approved and in current clinical use, commonly for skin infections, bone and joint infections, and as an alternative in patients allergic to penicillins.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single 300 mg oral dose of clindamycin.</p><h4>References</h4><ol><li><p>Bassetti, M, et al., &amp; Giacobbe, DR (2022). Current pharmacotherapy for methicillin-resistant . <i>Expert opinion on pharmacotherapy</i> 23(3) 361–375. DOI:<a href=\"https://doi.org/10.1080/14656566.2021.2010706\">10.1080/14656566.2021.2010706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34882041/\">https://pubmed.ncbi.nlm.nih.gov/34882041</a></p></li><li><p>Batzias, GC, et al., &amp; Athanasiou, LV (2005). Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs. <i>Veterinary journal (London, England : 1997)</i> 170(3) 339–345. DOI:<a href=\"https://doi.org/10.1016/j.tvjl.2004.06.007\">10.1016/j.tvjl.2004.06.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16266847/\">https://pubmed.ncbi.nlm.nih.gov/16266847</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Clindamycin;
